Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of < em > FLT3 < /em >

CONCLUSION: Although the overall improvement in RFS was not statistically significant, RFS was higher for participants with detectable FLT3-ITD MRD pre- or post-HCT who received gilteritinib treatment. To our knowledge, these data are among the first to support the effectiveness of MRD-based post-HCT therapy.PMID:38471061 | DOI:10.1200/JCO.23.02474

Source: Clinical Lung Cancer - March 12, 2024 Category: Cancer & Oncology Authors: Mark J Levis Mehdi Hamadani Brent Logan Richard J Jones Anurag K Singh Mark Litzow John R Wingard Esperanza B Papadopoulos Alexander E Perl Robert J Soiffer Celalettin Ustun Masumi Ueda Oshima Geoffrey L Uy Edmund K Waller Sumithra Vasu Melhem Solh Asmita Source Type: research